NCT06833411View on ClinicalTrials.gov

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2032

Conditions
Giant Cell Arteritis (GCA)
Interventions
DRUG

Prednisone

Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.

DRUG

Prednisone

Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.

Trial Locations (1)

Unknown

Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER